National Institutes of Health (NIH) Office of Science Policy (OSP): Request for Information on Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning, 45003-45005 [2024-11188]
Download as PDF
<![CDATA[
45003
Federal Register / Vol. 89, No. 100 / Wednesday, May 22, 2024 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents
Information collection forms
PHS 398 Career Development Award Supplemental Form ............................
PHS Human Subjects and Clinical Trial Information .......................................
Biosketch (424 Electronic) ...............................................................................
Data Management and Sharing Plan ..............................................................
Average
burden per
response
(in hours)
Number of
responses per
respondent
2,251
54,838
80,946
73,117
Total annual
burden hours
1
1
1
1
10
13
2
2
22,510
712,894
161,892
146,234
6,707
6,707
29
6,707
6,217
6
1,500
1
1
1
1
1
1
1
13
2
10
5/60
5/60
5/60
15/60
87,191
13,414
290
559
518
1
375
239
........................
1
486,749
11
........................
2,629
2,175,670
PHS Fellowship—Electronic
PHS Fellowship Supplemental Form (includes F reference letters) ...............
Biosketch (Fellowship) .....................................................................................
416–1 ...............................................................................................................
PHS 416–5 ......................................................................................................
PHS 6031 ........................................................................................................
VCOC Certification ..........................................................................................
SBIR/STTR Funding Agreement Certification .................................................
NIH Other Transaction
NIH Other Transaction Application Form ........................................................
Total Annual Burden Hours ......................................................................
Dated: May 13, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2024–11251 Filed 5–21–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; HEAL Initiative: Nonaddictive Analgesic Therapeutics
Development [Small Molecules and
Biologics] to Treat Pain.
Date: June 17, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
VerDate Sep<11>2014
17:06 May 21, 2024
Jkt 262001
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: W. Ernest Lyons, Ph.D.,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Activities, NINDS/NIH/DHHS, NSC, 6001
Executive Boulevard, Rockville, MD 20852,
301–496–4056, lyonse@ninds.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS).
Dated: May 16, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–11187 Filed 5–21–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health (NIH)
Office of Science Policy (OSP):
Request for Information on Draft NIH
Intramural Research Program Policy:
Promoting Equity Through Access
Planning
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institutes of
Health (NIH) is proposing to develop
and implement a new policy within its
Intramural Research Program (IRP) to
promote access to products stemming
SUMMARY:
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
from taxpayer-funded inventions. NIH
seeks input on this draft policy and
accompanying draft license agreement
language that incorporates patient
access in the commercialization process
for NIH-owned inventions.
DATES: To ensure consideration,
comments must be submitted in writing
by July 22, 2024.
ADDRESSES: Comments may be
submitted electronically to Https://osp.
od.nih.gov/comment-form-draft-nihintramural-research-program-policypromoting-equity-through-accessplanning/. Responses to this request for
information are voluntary and may be
submitted anonymously. You may
voluntarily include your name and
contact information with your response.
Other than your name and contact
information, please do not include in
the response any personally identifiable
information or any information that you
do not wish to make public. Proprietary,
classified, confidential, or sensitive
information should not be included in
your response. After the Office of
Science Policy (OSP) has finished
reviewing the responses, the responses
may be posted to the OSP website
without redaction.
FOR FURTHER INFORMATION CONTACT:
Abby Rives, Director of the Technology
Transfer and Innovation Policy, at (301)
496–9838 or SciencePolicy@od.nih.gov.
SUPPLEMENTARY INFORMATION:
Background
As the world’s largest public funder of
biomedical research, NIH seeks to drive
effective partnerships that foster a
shared commitment to transforming
E:\FR\FM\22MYN1.SGM
22MYN1
45004
Federal Register / Vol. 89, No. 100 / Wednesday, May 22, 2024 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
knowledge into improved health for all.
These investments are critical to the
health of our scientific enterprise, both
in terms of supporting research
discoveries and by fueling U.S.
leadership in the bioeconomy. Indeed,
NIH-owned inventions have provided
the foundation for new vaccines, drugs,
and medical devices.1 A recent report
estimated that technology licensed from
the IRP supported an average of 74,500
jobs and contributed an average of over
$13 billion to U.S. GDP each year over
the last two decades.2
NIH recognizes that all too often,
however, patients across the country
and across the globe may be unable to
access products they need—a treatment
for their disease may not yet exist, or it
might exist but be out of reach because
it is too expensive or difficult to take.
For example, millions of adults skip
medications due to high costs, and the
rising cost of prescription drugs puts
many of these products out of reach.
Thus, NIH is exploring how it might
leverage partnerships to further enhance
health through the biomedical research
it funds.
In 2023, NIH hosted a workshop in
support of this agenda, Transforming
Discoveries into Products: Maximizing
NIH’s Levers to Catalyze Technology
Transfer (https://osp.od.nih.gov/events/
workshop-on-transforming-discoveriesinto-products-maximizing-nihs-leversto-catalyze-technology-transfer/), to
discuss policies and practices that shape
biomedical innovation and promote
access to NIH-funded discoveries. At
this workshop, NIH heard from
participants with experience using
‘‘access planning’’ as a means to
prospectively address downstream
access challenges. Access planning
involves incorporating patient access
considerations, at a high level, in
agreements related to biomedical
research and development. The parties
commit to revisit access considerations
as product development progresses, but
the initial agreement terms are
intentionally flexible and not
prescriptive.
NIH is proposing a new policy within
the NIH IRP (see Appendix), to require
that licensees that succeed in bringing
certain products toward market submit
a plan outlining steps they intend to
1 HHS License-Based Vaccines & Therapeutics,
NATIONAL INSTITUTES OF HEALTH
TECHNOLOGY TRANSFER, https://www.tech
transfer.nih.gov/reportsstats/hhs-license-basedvaccines-therapeutics (last visited May 2, 2024).
2 Public Health & Economic Impact Study,
NATIONAL INSTITUTES OF HEALTH
TECHNOLOGY TRANSFER (May 2023), https://
www.techtransfer.nih.gov/reports/public-healthand-economic-impact-study.
VerDate Sep<11>2014
17:06 May 21, 2024
Jkt 262001
take to promote patient access to those
products. This new IRP policy makes it
clear that access, defined broadly to
include product affordability,
availability, acceptability, and
sustainability, is of paramount
importance in providing a return on
taxpayers’ investment in biomedical
research. This new policy would apply
to patent licenses for the
commercialization of drugs, biologics,
vaccines, or devices. NIH would also
employ a tiered approach, where
licenses granted for late-stage inventions
that are closer to market launch would
include more specific, tailored accessoriented provisions, while licenses
granted for early-stage inventions would
be more flexible to reflect the higher
uncertainty associated with
technologies that lead to drugs,
biologics, vaccines, or devices.
Importantly, a final policy approach
should be reasonable and not seek to
force licensees into access obligations
that obstruct commercial development
or damage the viability and
sustainability of a product in the
market, while also balancing the need to
promote access through reforms to
various policies. The agency is
proposing a flexible approach that
allows appropriately tailored,
commercially reasonable strategies to
promote patient access across a range of
technologies. This RFI is in relation to
the licensing of government-owned
inventions in accordance with 35 U.S.C.
207 and 37 CFR part 404.
Request for Information
NIH seeks information from all
interested individuals and communities,
including, but not limited to, patients
and patient advocates, small business
firms, technology transfer and licensing
professionals, investigators, public
health organizations, investors, industry
partners, healthcare providers,
universities, research institutions, and
other members of the public. While
comments are welcome on all elements
of this proposal, input would be most
welcome on the specific issues
identified below:
1. Promoting meaningful access
approaches. NIH intends to provide
additional guidance to licensees on
examples of acceptable, commercially
reasonable approaches for promoting
access. NIH is seeking input on the
range of activities that could be
considered and strategies to mitigate
access challenges and expand the reach,
and benefit, of drugs, biologics,
vaccines, and devices stemming from
NIH inventions.
2. Promoting transparency in the
biomedical research enterprise and
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
return on investment. The process of
bringing a new product through
research and development, to market,
and into the hands of patients is long,
fraught with challenges, and expensive.
NIH is interested in hearing from
potential partners on how access plans
could incorporate transparent cost
accounting measures to assist NIH in
driving down costs associated with
innovation and making clearer what
costs are incurred along the way and
how those affect product costs.
3. Providing flexibility while achieving
clear policy objectives. NIH recognizes
that its licensees, their partners, and the
public will need confidence around
what this policy requires and the
standards that would be used to
evaluate plans. The agency is seeking
input on how to maintain flexibility for
licensees to pursue their specific
product development and
commercialization needs while
simultaneously promoting certainty and
transparency on access efforts and
policy enforcement.
4. Helping licensees achieve access
goals. NIH is interested in hearing ideas
about how it may be able to help
licensees deliver patient access to
products that stem from these
agreements. Licensees could include
such information in access plans or at
earlier stages of product development.
NIH invites input on additional steps it
could take or ways to leverage existing
U.S. Government programs and
resources to assist in this endeavor.
5. Establishing licensee obligations
depending on the stage of technology
development. Generally, as a product
moves closer to market, the odds of
successful commercialization improve,
and NIH’s proposed policy would take
this into account. If the agency has
advanced products to the point of a first
pivotal clinical trials (e.g., Phase III or
the equivalent)—licenses covering those
products would include specific,
tailored access-oriented provisions that
should be clear and understandable.
NIH is seeking further input on specific
provisions that would meet these
objectives.
6. Assessing policy impact. NIH is
seeking input on how to assess
compliance with the proposed policy
and potential metrics for assessing its
impact.
Appendix: Proposed Aspects of Draft
NIH IRP Policy Promoting Equity
Through Access Planning
I. Policy Scope
NIH is proposing a new policy that would
apply to inventions made by investigators in
the NIH Intramural Research Program (IRP)
and owned by the agency. This policy would
E:\FR\FM\22MYN1.SGM
22MYN1
Federal Register / Vol. 89, No. 100 / Wednesday, May 22, 2024 / Notices
apply to commercial patent licenses that
authorize commercialization of drugs,
biologics, vaccines, or devices for the
prevention, diagnosis, or treatment of human
disease and would include exclusive, coexclusive, partially exclusive, and nonexclusive licenses. Third-party IP (i.e.,
patents solely owned by NIH’s collaborators
and partners) would be outside the scope of
this policy. Application of the proposed
policy to jointly-owned IP will be considered
at a later date.
khammond on DSKJM1Z7X2PROD with NOTICES
II. Policy Requirements
NIH proposes adding the following
language to NIH IRP model license
agreements within the scope of the policy:
‘‘Access Plan’’ means Licensee’s plan, and
incorporating the plan(s) of its sublicensee(s),
as applicable, that describes Licensee’s
strategy to support broad access to Licensed
Product(s) for the U.S. population, as well as
(a) through the lens of promoting equity for
underserved communities such as Black,
Latino, and Indigenous and Native American
persons, Asian Americans and Pacific
Islanders and other persons of color;
members of religious minorities; lesbian, gay,
bisexual, transgender, and queer (LGBTQ+)
persons; persons with disabilities; persons
who live in rural areas; and persons
otherwise adversely affected by persistent
poverty or inequality, as defined by
Executive Order 13985 and/or (b)
populations in low- and middle-income
countries, as defined using the World Bank
classification system.
The Access Plan shall include, but not be
limited to, a brief description of the Licensed
Product(s); the anticipated patient
population(s); other products, tools, facilities,
or unique resources that would be necessary
for use of the Licensed Product; and one or
more strategies to mitigate access challenges
across criteria including affordability,
availability, acceptability, and sustainability.
To the extent such Access Plan includes
proprietary information [to be defined], upon
NIH’s request Licensee will also provide a
non-confidential version or statement of such
Access Plan that NIH may publish or
otherwise make available to third parties.
Within 3 months of a Licensed Product
entering a first pivotal clinical trial (a Phase
III trial or the equivalent), Licensee will
provide NIH with an Access Plan (as
defined), unless a written waiver or
modification is obtained in advance from
NIH. NIH agrees to consider such requests for
waivers or modifications in good faith.
Within 30 days of NIH’s request (no more
often than once annually), Licensee agrees to
confer with NIH to review Licensee’s
progress, and to consider in good faith any
reasonable modifications suggested by NIH
with respect to the Access Plan.
III. Access Plans
Each product will be different, and patient
populations and access challenges will vary
by product. Access planning presents an
opportunity for NIH and its licensees to
proactively mitigate access challenges and
devise tailored strategies to expand the reach,
and benefit, of products. Accordingly, NIH
proposes developing guidance for acceptable
access plans.
VerDate Sep<11>2014
17:06 May 21, 2024
Jkt 262001
Potential strategies for licensees to
consider would include, but not be limited
to, one or more of the following:
• Partnering with public health, non-profit,
or patient advocacy organizations. Examples
could include partnerships during research
and development, regulatory approval, or
sales and marketing; selling product to
organizations that treat underserved
populations (e.g., Federally Qualified Health
Centers); or licensing intellectual property to
public health patent pools (e.g., Medicines
Patent Pool).
• Addressing accessibility as a design
objective. Examples could include
conducting patient interviews or needs
assessments early in development or
strategically making product development
choices (e.g., single dose) or business choices
(e.g., pricing structures) to promote patient
access.
• Committing to sublicense relevant
intellectual property and know-how.
Examples could include sublicensing to
manufacturers in additional countries or
world regions on voluntary and mutually
agreed to terms; committing to license all
intellectual property and know-how needed
to make a product if the licensee exits a
market; or agreeing to sublicense relevant
intellectual property on a low- or no-royalty
basis.
• Entering purchasing partnerships or
commitments. Examples could include
committing to supply product in a given
market(s) for a designated duration; agreeing
to coordinate and set aside a portion of
manufactured product for donation or sale to
a partner organization on a cost-plus basis; or
agreeing to sell a designated volume of
product to the U.S. Government or another
designated entity on a cost-plus basis.
• Submitting additional
commercialization plans targeted to other
markets. Examples could include offering
product development timelines to develop
formulations that meet a population’s unique
needs or committing to a plan for developing
suitable products for additional users.
• Promoting equitable access and
affordability in product development and
deployment. Examples could include
committing to keep prices in the U.S. equal
to those in other developed countries; not
raising costs above inflation; preparing
tailored, culturally sensitive educational
materials for a range of domestic and global
patient populations.
Access plans might include requests for
additional support or facilitation to advance
access goals. For example, licensees might
seek connections to preclinical or clinical
trial resources NIH offers, help in developing
their access plans, or connections to partner
organizations well-versed in access
considerations relevant to the technology in
question.
Access plans might also address research
outputs or other benefit sharing, including
public access to publications, data sharing, or
community-led or international collaboration
in research. Such commitments might
supplement, but not replace, patient-focused
elements proposed above.
NIH also proposes to include a process for
licensees to request a waiver or modification
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
45005
of the access planning provision, in whole or
in part. The agency would consider such
requests on a case-by-case basis and evaluate
them according to criteria that would be
identified in the guidance for access plans.
IV. Assessing Efforts To Address Access
NIH recognizes that myriad factors affect
access to emerging biomedical technologies,
such as:
• Affordability. For example, can patients
afford the intended product(s), taking into
account factors such as pricing structure,
insurance, reimbursement, coverage
decisions, payment models, and/or
international price comparators?
• Availability. For example, are products
in existence, able to be manufactured, widely
available on the market, and approved for
sale and distributed across geographical
regions?
• Acceptability. For example, are products
developed and/or delivered in a manner that
resonates with end users and is tolerated for
the duration of use? Are there effective
systems for safely delivering the product?
• Sustainability. For example, are there
predictable and stable infrastructure at local
levels for enabling and maintaining the above
elements of access?
NIH does not expect licensees to address
each issue but instead address elements of
patient access that are relevant to the specific
product in question to expand access.
Dated: May 16, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2024–11188 Filed 5–21–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Office of AIDS Research
Advisory Council.
The meeting will be held as a virtual
meeting and will be open to the public
as indicated below. Individuals who
plan to view the virtual meeting and
need special assistance or other
reasonable accommodations to view the
meeting, should notify the Contact
Person listed below in advance of the
meeting. The meeting can be accessed
from the NIH Videocast at the following
link: https://videocast.nih.gov/.
Name of Committee: Office of AIDS
Research Advisory Council.
Date: June 20, 2024.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: The sixty-sixth meeting of the
Office of AIDS Research Advisory Council
(OARAC) will include a brief report from the
E:\FR\FM\22MYN1.SGM
22MYN1
]]>Agencies
[Federal Register Volume 89, Number 100 (Wednesday, May 22, 2024)]
[Notices]
[Pages 45003-45005]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11188]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institutes of Health (NIH) Office of Science Policy
(OSP): Request for Information on Draft NIH Intramural Research Program
Policy: Promoting Equity Through Access Planning
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institutes of Health (NIH) is proposing to
develop and implement a new policy within its Intramural Research
Program (IRP) to promote access to products stemming from taxpayer-
funded inventions. NIH seeks input on this draft policy and
accompanying draft license agreement language that incorporates patient
access in the commercialization process for NIH-owned inventions.
DATES: To ensure consideration, comments must be submitted in writing
by July 22, 2024.
ADDRESSES: Comments may be submitted electronically to Https://osp.od.nih.gov/comment-form-draft-nih-intramural-research-program-policy-promoting-equity-through-access-planning/. Responses to this
request for information are voluntary and may be submitted anonymously.
You may voluntarily include your name and contact information with your
response. Other than your name and contact information, please do not
include in the response any personally identifiable information or any
information that you do not wish to make public. Proprietary,
classified, confidential, or sensitive information should not be
included in your response. After the Office of Science Policy (OSP) has
finished reviewing the responses, the responses may be posted to the
OSP website without redaction.
FOR FURTHER INFORMATION CONTACT: Abby Rives, Director of the Technology
Transfer and Innovation Policy, at (301) 496-9838 or
[email protected].
SUPPLEMENTARY INFORMATION:
Background
As the world's largest public funder of biomedical research, NIH
seeks to drive effective partnerships that foster a shared commitment
to transforming
[[Page 45004]]
knowledge into improved health for all. These investments are critical
to the health of our scientific enterprise, both in terms of supporting
research discoveries and by fueling U.S. leadership in the bioeconomy.
Indeed, NIH-owned inventions have provided the foundation for new
vaccines, drugs, and medical devices.\1\ A recent report estimated that
technology licensed from the IRP supported an average of 74,500 jobs
and contributed an average of over $13 billion to U.S. GDP each year
over the last two decades.\2\
---------------------------------------------------------------------------
\1\ HHS License-Based Vaccines & Therapeutics, NATIONAL
INSTITUTES OF HEALTH TECHNOLOGY TRANSFER, https://www.techtransfer.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics (last visited May 2, 2024).
\2\ Public Health & Economic Impact Study, NATIONAL INSTITUTES
OF HEALTH TECHNOLOGY TRANSFER (May 2023), https://www.techtransfer.nih.gov/reports/public-health-and-economic-impact-study.
---------------------------------------------------------------------------
NIH recognizes that all too often, however, patients across the
country and across the globe may be unable to access products they
need--a treatment for their disease may not yet exist, or it might
exist but be out of reach because it is too expensive or difficult to
take. For example, millions of adults skip medications due to high
costs, and the rising cost of prescription drugs puts many of these
products out of reach. Thus, NIH is exploring how it might leverage
partnerships to further enhance health through the biomedical research
it funds.
In 2023, NIH hosted a workshop in support of this agenda,
Transforming Discoveries into Products: Maximizing NIH's Levers to
Catalyze Technology Transfer (https://osp.od.nih.gov/events/workshop-on-transforming-discoveries-into-products-maximizing-nihs-levers-to-catalyze-technology-transfer/), to discuss policies and practices that
shape biomedical innovation and promote access to NIH-funded
discoveries. At this workshop, NIH heard from participants with
experience using ``access planning'' as a means to prospectively
address downstream access challenges. Access planning involves
incorporating patient access considerations, at a high level, in
agreements related to biomedical research and development. The parties
commit to revisit access considerations as product development
progresses, but the initial agreement terms are intentionally flexible
and not prescriptive.
NIH is proposing a new policy within the NIH IRP (see Appendix), to
require that licensees that succeed in bringing certain products toward
market submit a plan outlining steps they intend to take to promote
patient access to those products. This new IRP policy makes it clear
that access, defined broadly to include product affordability,
availability, acceptability, and sustainability, is of paramount
importance in providing a return on taxpayers' investment in biomedical
research. This new policy would apply to patent licenses for the
commercialization of drugs, biologics, vaccines, or devices. NIH would
also employ a tiered approach, where licenses granted for late-stage
inventions that are closer to market launch would include more
specific, tailored access-oriented provisions, while licenses granted
for early-stage inventions would be more flexible to reflect the higher
uncertainty associated with technologies that lead to drugs, biologics,
vaccines, or devices. Importantly, a final policy approach should be
reasonable and not seek to force licensees into access obligations that
obstruct commercial development or damage the viability and
sustainability of a product in the market, while also balancing the
need to promote access through reforms to various policies. The agency
is proposing a flexible approach that allows appropriately tailored,
commercially reasonable strategies to promote patient access across a
range of technologies. This RFI is in relation to the licensing of
government-owned inventions in accordance with 35 U.S.C. 207 and 37 CFR
part 404.
Request for Information
NIH seeks information from all interested individuals and
communities, including, but not limited to, patients and patient
advocates, small business firms, technology transfer and licensing
professionals, investigators, public health organizations, investors,
industry partners, healthcare providers, universities, research
institutions, and other members of the public. While comments are
welcome on all elements of this proposal, input would be most welcome
on the specific issues identified below:
1. Promoting meaningful access approaches. NIH intends to provide
additional guidance to licensees on examples of acceptable,
commercially reasonable approaches for promoting access. NIH is seeking
input on the range of activities that could be considered and
strategies to mitigate access challenges and expand the reach, and
benefit, of drugs, biologics, vaccines, and devices stemming from NIH
inventions.
2. Promoting transparency in the biomedical research enterprise and
return on investment. The process of bringing a new product through
research and development, to market, and into the hands of patients is
long, fraught with challenges, and expensive. NIH is interested in
hearing from potential partners on how access plans could incorporate
transparent cost accounting measures to assist NIH in driving down
costs associated with innovation and making clearer what costs are
incurred along the way and how those affect product costs.
3. Providing flexibility while achieving clear policy objectives.
NIH recognizes that its licensees, their partners, and the public will
need confidence around what this policy requires and the standards that
would be used to evaluate plans. The agency is seeking input on how to
maintain flexibility for licensees to pursue their specific product
development and commercialization needs while simultaneously promoting
certainty and transparency on access efforts and policy enforcement.
4. Helping licensees achieve access goals. NIH is interested in
hearing ideas about how it may be able to help licensees deliver
patient access to products that stem from these agreements. Licensees
could include such information in access plans or at earlier stages of
product development. NIH invites input on additional steps it could
take or ways to leverage existing U.S. Government programs and
resources to assist in this endeavor.
5. Establishing licensee obligations depending on the stage of
technology development. Generally, as a product moves closer to market,
the odds of successful commercialization improve, and NIH's proposed
policy would take this into account. If the agency has advanced
products to the point of a first pivotal clinical trials (e.g., Phase
III or the equivalent)--licenses covering those products would include
specific, tailored access-oriented provisions that should be clear and
understandable. NIH is seeking further input on specific provisions
that would meet these objectives.
6. Assessing policy impact. NIH is seeking input on how to assess
compliance with the proposed policy and potential metrics for assessing
its impact.
Appendix: Proposed Aspects of Draft NIH IRP Policy Promoting Equity
Through Access Planning
I. Policy Scope
NIH is proposing a new policy that would apply to inventions
made by investigators in the NIH Intramural Research Program (IRP)
and owned by the agency. This policy would
[[Page 45005]]
apply to commercial patent licenses that authorize commercialization
of drugs, biologics, vaccines, or devices for the prevention,
diagnosis, or treatment of human disease and would include
exclusive, co-exclusive, partially exclusive, and non-exclusive
licenses. Third-party IP (i.e., patents solely owned by NIH's
collaborators and partners) would be outside the scope of this
policy. Application of the proposed policy to jointly-owned IP will
be considered at a later date.
II. Policy Requirements
NIH proposes adding the following language to NIH IRP model
license agreements within the scope of the policy:
``Access Plan'' means Licensee's plan, and incorporating the
plan(s) of its sublicensee(s), as applicable, that describes
Licensee's strategy to support broad access to Licensed Product(s)
for the U.S. population, as well as (a) through the lens of
promoting equity for underserved communities such as Black, Latino,
and Indigenous and Native American persons, Asian Americans and
Pacific Islanders and other persons of color; members of religious
minorities; lesbian, gay, bisexual, transgender, and queer (LGBTQ+)
persons; persons with disabilities; persons who live in rural areas;
and persons otherwise adversely affected by persistent poverty or
inequality, as defined by Executive Order 13985 and/or (b)
populations in low- and middle-income countries, as defined using
the World Bank classification system.
The Access Plan shall include, but not be limited to, a brief
description of the Licensed Product(s); the anticipated patient
population(s); other products, tools, facilities, or unique
resources that would be necessary for use of the Licensed Product;
and one or more strategies to mitigate access challenges across
criteria including affordability, availability, acceptability, and
sustainability. To the extent such Access Plan includes proprietary
information [to be defined], upon NIH's request Licensee will also
provide a non-confidential version or statement of such Access Plan
that NIH may publish or otherwise make available to third parties.
Within 3 months of a Licensed Product entering a first pivotal
clinical trial (a Phase III trial or the equivalent), Licensee will
provide NIH with an Access Plan (as defined), unless a written
waiver or modification is obtained in advance from NIH. NIH agrees
to consider such requests for waivers or modifications in good
faith.
Within 30 days of NIH's request (no more often than once
annually), Licensee agrees to confer with NIH to review Licensee's
progress, and to consider in good faith any reasonable modifications
suggested by NIH with respect to the Access Plan.
III. Access Plans
Each product will be different, and patient populations and
access challenges will vary by product. Access planning presents an
opportunity for NIH and its licensees to proactively mitigate access
challenges and devise tailored strategies to expand the reach, and
benefit, of products. Accordingly, NIH proposes developing guidance
for acceptable access plans.
Potential strategies for licensees to consider would include,
but not be limited to, one or more of the following:
Partnering with public health, non-profit, or patient
advocacy organizations. Examples could include partnerships during
research and development, regulatory approval, or sales and
marketing; selling product to organizations that treat underserved
populations (e.g., Federally Qualified Health Centers); or licensing
intellectual property to public health patent pools (e.g., Medicines
Patent Pool).
Addressing accessibility as a design objective.
Examples could include conducting patient interviews or needs
assessments early in development or strategically making product
development choices (e.g., single dose) or business choices (e.g.,
pricing structures) to promote patient access.
Committing to sublicense relevant intellectual property
and know-how. Examples could include sublicensing to manufacturers
in additional countries or world regions on voluntary and mutually
agreed to terms; committing to license all intellectual property and
know-how needed to make a product if the licensee exits a market; or
agreeing to sublicense relevant intellectual property on a low- or
no-royalty basis.
Entering purchasing partnerships or commitments.
Examples could include committing to supply product in a given
market(s) for a designated duration; agreeing to coordinate and set
aside a portion of manufactured product for donation or sale to a
partner organization on a cost-plus basis; or agreeing to sell a
designated volume of product to the U.S. Government or another
designated entity on a cost-plus basis.
Submitting additional commercialization plans targeted
to other markets. Examples could include offering product
development timelines to develop formulations that meet a
population's unique needs or committing to a plan for developing
suitable products for additional users.
Promoting equitable access and affordability in product
development and deployment. Examples could include committing to
keep prices in the U.S. equal to those in other developed countries;
not raising costs above inflation; preparing tailored, culturally
sensitive educational materials for a range of domestic and global
patient populations.
Access plans might include requests for additional support or
facilitation to advance access goals. For example, licensees might
seek connections to preclinical or clinical trial resources NIH
offers, help in developing their access plans, or connections to
partner organizations well-versed in access considerations relevant
to the technology in question.
Access plans might also address research outputs or other
benefit sharing, including public access to publications, data
sharing, or community-led or international collaboration in
research. Such commitments might supplement, but not replace,
patient-focused elements proposed above.
NIH also proposes to include a process for licensees to request
a waiver or modification of the access planning provision, in whole
or in part. The agency would consider such requests on a case-by-
case basis and evaluate them according to criteria that would be
identified in the guidance for access plans.
IV. Assessing Efforts To Address Access
NIH recognizes that myriad factors affect access to emerging
biomedical technologies, such as:
Affordability. For example, can patients afford the
intended product(s), taking into account factors such as pricing
structure, insurance, reimbursement, coverage decisions, payment
models, and/or international price comparators?
Availability. For example, are products in existence,
able to be manufactured, widely available on the market, and
approved for sale and distributed across geographical regions?
Acceptability. For example, are products developed and/
or delivered in a manner that resonates with end users and is
tolerated for the duration of use? Are there effective systems for
safely delivering the product?
Sustainability. For example, are there predictable and
stable infrastructure at local levels for enabling and maintaining
the above elements of access?
NIH does not expect licensees to address each issue but instead
address elements of patient access that are relevant to the specific
product in question to expand access.
Dated: May 16, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes of Health.
[FR Doc. 2024-11188 Filed 5-21-24; 8:45 am]
BILLING CODE 4140-01-P
